cutaneous T-cell lymphoma (CTCL)

From Aaushi
Jump to navigation Jump to search

Etiology

Clinical manifestations

Laboratory

Radiology

Complications

Management

* purine analog, histone deacetylase inhibitor, monoclonal Ab

More general terms

More specific terms

Additional terms

References

  1. Jump up to: 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Aljishi M, Barrow C Cutaneous T-Cell Lymphoma N Engl J Med 2015; 372:2437. June 18, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26083208 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMicm1406401
  2. Jump up to: 2.0 2.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
  3. Jump up to: 3.0 3.1 3.2 Wu J, Wood GS. Analysis of the Effect of Gentian Violet on Apoptosis and Proliferation in Cutaneous T-Cell Lymphoma in an In Vitro Study. JAMA Dermatol. Published online August 29, 2018. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30167641 https://jamanetwork.com/journals/jamadermatology/fullarticle/2697566
  4. Jump up to: 4.0 4.1 Garlewicz J Cutaneous T-Cell Lymphoma and Psoriasis Associated With Memory Impairment. The Dermatologist. Aug 8, 2022 https://www.hmpgloballearningnetwork.com/site/thederm/news/cutaneous-t-cell-lymphoma-and-psoriasis-associated-memory-impairment
    Damiani G, Tacastacas JD, Wuerz T et al. Cognition/psychological burden and resilience in cutaneous T-cell lymphoma and psoriasis patients: real-life data and implications for the treatment. Biomed Res Int. Published online July 21, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35937394 PMCID: PMC9348939 Free PMC article

Patient information

cutaneous T-cell lymphoma patient information